Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial

作者
Rui Han,Jianghua Li,Yubo Wang,Tingting He,Jie Zheng,Yong He
出处
期刊:Chinese Medical Journal Pulmonary and Critical Care Medicine [Elsevier BV]
卷期号:1 (2): 119-124 被引量:5
标识
DOI:10.1016/j.pccm.2023.04.006
摘要

The synergistic association between metformin and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has been confirmed in in vitro studies. It is still controversial which patients can benefit from metformin plus EGFR-TKIs treatment. Body mass index (BMI) was proved to be independently associated with prolonged progression-free survival (PFS) and overall survival (OS). This study aimed to investigate whether BMI is associated with the synergistic effect of metformin and EGFR-TKIs in advanced EGFR mutation (EGFRm)-positive non-small cell lung cancer (NSCLC) among nondiabetic Asian population. We performed a post hoc analysis of a prospective, double-blind phase II randomized clinical trial (COAST, NCT01864681), which enrolled 224 patients without diabetes with treatment-naïve stage IIIB-IV EGFRm NSCLC. We stratified patients into those with a high BMI (≥24 kg/m2) and those with a low BMI (<24 kg/m2) to allow an analysis of the difference in PFS and OS between the two groups. The PFS and OS were analyzed using Kaplan–Meier curves, and the differences between groups were compared using log-rank test. In the univariate analysis, patients who had a high BMI (n = 56) in the gefitinib + metformin group (n = 28) did not have a better PFS (8.84 months vs. 11.67 months; P = 0.351) or OS (15.58 months vs. 24.36 months; P = 0.095) than those in the gefitinib + placebo group (n = 28). Similar results were also observed in the low-BMI groups. Strikingly, in the metformin plus gefitinib group, patients who had low BMI (n = 69) showed significantly better OS than those with high BMI (24.89 months [95% CI, 20.68 months–not reached] vs. 15.58 months [95% CI, 13.78–31.53 months]; P = 0.007), but this difference was not observed in PFS (10.78 months vs. 8.84 months; P = 0.285). Our study showed that nondiabetic Asian advanced NSCLC patients with EGFR mutations who have low BMI seem to get better OS from metformin plus EGFR-TKI treatment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
旭东静静发布了新的文献求助10
刚刚
1秒前
1秒前
SciGPT的应助被公孙世往采纳,获得10
1秒前
1秒前
1秒前
1秒前
1秒前
1秒前
有尾的无尾熊完成签到,获得积分10
1秒前
秋风的应助被追寻的钥匙采纳,获得20
2秒前
无极微光的应助被橘子采纳,获得20
2秒前
3秒前
CITY111119发布了新的文献求助10
3秒前
3秒前
4秒前
summer完成签到 ,获得积分10
4秒前
一生所爱发布了新的文献求助10
4秒前
alexwumk发布了新的文献求助10
5秒前
乐观冥幽发布了新的文献求助10
6秒前
呆萌画笔完成签到,获得积分10
6秒前
6秒前
焦哈哈完成签到,获得积分10
7秒前
Aurora发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
Everglow发布了新的文献求助10
9秒前
Yy杨优秀完成签到 ,获得积分10
9秒前
soory完成签到,获得积分10
10秒前
CipherSage的应助被denty采纳,获得10
11秒前
11秒前
加油干完成签到,获得积分10
12秒前
哈47发布了新的文献求助10
12秒前
Lynn发布了新的文献求助10
12秒前
乐观冥幽完成签到,获得积分10
13秒前
樱桃完成签到 ,获得积分10
13秒前
cc发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621